Eximia Research Network has announced the acquisition of Tidewater Clinical Research, marking a significant expansion of its national clinical trial site network.

Established in 1994, Tidewater Clinical Research focuses on Women's Health and Ophthalmology clinical trials in the Hampton Roads/Eastern Virginia region in the US.

The integration of Tidewater's capabilities and patient database with Eximia’s extensive resources is expected to enhance clinical trial experiences.

Tidewater owner Kelley Fleming said: “Tidewater Clinical Research is proud to announce our integration into the Eximia Research Network, marking a significant step forward in enhancing clinical research accessibility and quality of care for diverse patient populations.”

Tidewater co-owner April Rusch said: “Under the Eximia umbrella, Tidewater is poised to broaden its impact on patient health and contribute to the advancement of medical research in ever-expanding medical subspecialty areas.”

For the transaction, David Bogart and Devak Patel from Viking Mergers & Acquisitions served as advisers.

Viking Mergers & Acquisitions, which has been in operation since 1996, is a business broker in the Southeast US. It has a track record of having sold over 850 businesses.

Eximia Research Network CEO Dr Ella Grach said: “We are excited to welcome Tidewater Clinical Research to the Eximia network.

“Their expertise in Women's Health and Ophthalmology complements our mission to drive innovation and improve patient outcomes. This acquisition enhances our ability to serve diverse populations and support groundbreaking clinical research nationwide.”

In October last year, Eximia secured a growth capital investment from private investment company VSS Capital Partners (VSS).

The companies did not disclose the financial terms of the deal.